Quanterix Corporation (NASDAQ:QTRX) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET

Company Participants

Mike Doyle - CFO

Masoud Toloue - President & CEO

Conference Call Participants

Max Masucci - Cowen and Company

Kyle Mikson - Canaccord

Matt Sykes - Goldman Sachs

Puneet Souda - SVB Leerink

Operator

Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Mike Doyle, Quanterix CFO.

Mike Doyle

Good morning , everyone, and thanks for joining us today. With me on today's call is Masoud Toloue, President and CEO of Quanterix. Before we begin, I would like to remind you about a few things. The call will be recorded and will be available on the Investor Resources section of our website. Today's call will contain forward-looking statements that are based on management's beliefs and assumptions and on information available as of the date of this call. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission.

With that, I will turn the call over to Masoud.

Masoud Toloue

Thanks, Mike and good morning. Before we start, I'd like to thank Kevin and the Board for their support in this new chapter at Quanterix. Kevin's dedication and passion for this company and its impact on health care goals are shared. I look forward to working with him, the Board, our employees and customers.

Since I joined Quanterix last year and transitioned to this new role, two weeks ago, what has been very clear to me is that our ultra-sensitive single molecule array Simoa technology is being used every day to see, detect and measure of proteins in a way that's unparalleled. But it's how we effectively deploy this technology that counts. This includes unlocking new biomarkers, playing a key role and breakthrough research, and ultimately developing tests that will have a significant impact on the human condition.